非小细胞肺癌患者p53蛋白异常表达与铂类化疗敏感性的Meta分析

目的 探讨非小细胞肺癌(NSCLC)中p53蛋白表达与对铂类化疗敏感性的关系.方法 应用Meta分析DerSimonian-Laird分析模型对有关NSCLC中p53蛋白表达与对铂类化疗敏感性的文献进行综合定量评价.结果 人选16篇文献共1070例患者,p53阳性患者539例,p53阳性率50.4％.铂类化疗有效患者414例,合并有效率38.7％.异质性检验显示x2=47.57,P<0.0001,文献具有异质性,采用随机效应模型DerSimonian-Laird法进行分析,合并优势比(OR)为1.37,95％可信区间0.84～2.24.结论 NSCLC中p53蛋白阴性表达患者对铂类药物化疗敏感性并不明显优于p53蛋白阳性患者.

p53 protein expression and chemosensitivity to cisplatin in patients with non-small cell lung cancer:a Meta-analysis

OBJECTIVE: To explore the relation between p53 protein expression and chemosensitivity to cisplatin in patients with non-small cell lung cancer (NSCLC). METHODS: The DerSimonian-Laird random effect model was used to analyze the data reported in relevant literature. RESULTS: Sixteen trials involving 1070 patients were retrieved. The overall positivity rate of p53 was 50.4% and overall response rate to cisplatin was 38.7%. The test for heterogeneity showed that all eligible studies had heterogeneity (chi 2-/+47.57, P<0.0001). The combined odds ratio (OR) was 1.37, with 95% confidence interval of 0.84-2.24. CONCLUSION: Expression of p53 protein in patients with NSCLC is not associated with the chemosensitivity to cisplatin.